Biocon Biologics wraps up integration of Viatris’ biosimilars business in Europe
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful completion of the integration of Viatris’ biosimilars business across 31 European countries. ... Read More
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars business from Viatris in over 70 countries ... Read More
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability of its biosimilar injection, HULIO (adalimumab-fkjp), in ... Read More
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo Inc. for commercializing a couple of its ... Read More